AB
The startup develops antibody biotherapeutics targeting B cell cancers, inflammatory and metabolic disorders, and chronic hepatitis B infections. By providing clinical development support, the company enhances treatment options for patients facing these life-threatening diseases.
Updated 2 months ago
Funding
$60M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops antibody biotherapeutics targeting B cell cancers, inflammatory and metabolic disorders, and chronic hepatitis B infections. By providing clinical development support, the company enhances treatment options for patients facing these life-threatening diseases.